Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Sci Rep ; 13(1): 14114, 2023 08 29.
Article in English | MEDLINE | ID: mdl-37644107

ABSTRACT

Salidroside is a natural product of phenols, which has a wide scape of pharmacological effects, but its pharmacological effects and molecular mechanism on endometrial cancer are not clear. To systematically explore the pharmacological effects and molecular mechanisms of salidroside on endometrial cancer through the method of network pharmacology. The possible target genes of salidroside were obtained through different pharmacological databases and analysis platforms, and then the relevant target genes of endometrial cancer were obtained through the GeneCards website, and the target genes were uniformly converted into standardized gene names with Uniprot. The collected data were then processed to obtain common target genes and further analyzed through the String website to construct a protein-protein interaction (PPI) network, followed by gene ontology (GO) functional annotation and Kyoto Gene and Genome Encyclopedia (KEGG) pathway analysis. We further interpreted the molecular mechanism of salidroside for the treatment of endometrial cancer by constructing a "drug component-target gene-disease" network. Finally, we performed molecular docking to validate the binding conformation between salidroside and the candidate target genes. There were 175 target genes of salidroside after normalization, among which 113 target genes interacted with endometrial cancer. GO analysis indicated that the anti-endometrial cancer effect of salidroside may be strongly related to biological processes such as apoptosis and response to drug. KEGG analysis indicated that its mechanism may be related to pathway in cancer and PI3K-AKT signaling pathway. Molecular docking showed that salidroside had high affinity with five key genes. Based on the novel network pharmacology and molecular docking validation research methods, we have revealed for the first time the potential mechanism of salidroside in the therapy of endometrial cancer.


Subject(s)
Endometrial Neoplasms , Network Pharmacology , Female , Humans , Molecular Docking Simulation , Phosphatidylinositol 3-Kinases , Endometrial Neoplasms/drug therapy , Endometrial Neoplasms/genetics , Phenols/pharmacology , Phenols/therapeutic use
2.
Biomed Pharmacother ; 123: 109717, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31865146

ABSTRACT

Previous studies have shown that cell adhesion molecule 1 (CADM1), an immunoglobulin superfamily member, is frequently inactivated but functions as a tumor suppressor in many solid tumors. However, the characterization of CADM1 expression in ovarian cancer cells and the mechanisms of its tumor suppressor function are not fully understood. We generated ovarian cancer cell lines in which CADM1 was stably upregulated or downregulated. CADM1 expression was significantly decreased in ovarian cancer tissue and cells lines. Functionally, knockdown of CADM1 promoted the growth, migration and invasion of ovarian cancer cells. Conversely, further experimental evidence indicated that overexpression of CADM1 inhibited the migration and invasion of ovarian cancer cells potentially through inhibition of the PI3K/Akt/mTOR signaling pathway by regulating upstream regulators (LXR/RXR, IGF1, IFI44L and C4BPA) and downstream effectors (APP, EDN1, TGFBI and Rap1A). In conclusion, CADM1 inhibits ovarian cancer cell proliferation and migration by potentially regulating the PI3K/Akt/mTOR signaling pathway. CADM1 could be a potential therapeutic target for ovarian cancer.


Subject(s)
Cell Adhesion Molecule-1/metabolism , Ovarian Neoplasms/metabolism , Phosphatidylinositol 3-Kinases/metabolism , TOR Serine-Threonine Kinases/metabolism , Cell Adhesion Molecule-1/genetics , Cell Line, Tumor , Cell Movement/physiology , Cell Proliferation/physiology , Down-Regulation , Epithelial Cells , Female , Gene Expression Regulation, Neoplastic/drug effects , Gene Silencing , Humans , Ovarian Neoplasms/genetics , Phosphatidylinositol 3-Kinases/genetics , Proto-Oncogene Proteins c-akt/genetics , Proto-Oncogene Proteins c-akt/metabolism , RNA, Messenger , TOR Serine-Threonine Kinases/genetics , Transcriptome
3.
Oncol Lett ; 18(3): 2477-2483, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31402947

ABSTRACT

Synaptic cell adhesion molecules (SynCAMs) are single transmembrane proteins that belong to the immunoglobulin superfamily of cell adhesion molecules. In the present study, a decrease in SynCAM levels in ovarian tumor tissues compared with normal tissues is reported; the downregulation was accompanied by the grade malignancy. The observations suggested that SynCAM may be essential for important novel functions in ovarian cancer. Further experiments showed that low SynCAM expression inhibited membrane palmitoylated protein 6 (MPP6) expression, a member of the palmitoylated membrane protein subfamily of peripheral membrane-associated guanylate kinases. In addition, low levels of MPP6 in ovarian tumor tissues correlated with shorter patient survival. A SynCAM-regulated pathway may provide molecular targets for the treatment of ovarian cancer and novel biomarkers to be used in clinical diagnosis.

4.
Future Oncol ; 15(14): 1577-1591, 2019 May.
Article in English | MEDLINE | ID: mdl-30859853

ABSTRACT

Aim: Research on novel mutant genes may develop the treatment of cervical cancer (CC). The role of miRNA-526b in epithelial-mesenchymal transition (EMT) of CC was investigated. Methods: The role and the molecular mechanism of miRNA-526b in CC and its effect on EMT were analyzed in clinical specimens and oncology experiments. Results: miRNA-526b was proved to be decreased in CC and associated with malignant clinicopathological characters. The character of miRNA-526b in EMT was also inspected in CC cells and tumor models. miRNA-526b was found to be able to inhibit the EMT property of CC cells by directly targeting PBX3. Conclusion: miRNA-526b restoration may be deliberated as a new treatment strategy of CC.


Subject(s)
Epithelial-Mesenchymal Transition/genetics , Gene Expression Regulation, Neoplastic , Homeodomain Proteins/genetics , MicroRNAs/genetics , Proto-Oncogene Proteins/genetics , RNA Interference , Uterine Cervical Neoplasms/genetics , Uterine Cervical Neoplasms/pathology , 3' Untranslated Regions , Adult , Aged , Animals , Cell Movement/genetics , Cell Proliferation/genetics , Disease Models, Animal , Female , Humans , Mice , Middle Aged , Neoplasm Metastasis , Neoplasm Staging
5.
Biomed Pharmacother ; 110: 139-144, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30469078

ABSTRACT

Nectin-3 is a cell adhesion molecule that functions in tight junctions. Recent reports have implicated nectin-3 in pancreatic adenocarcinoma and lung adenocarcinoma. However, there has been little exploration of the expression, cellular invasion and migration of nectin-3 in ovarian cancer (OC). We evaluated the distribution of cells that were positive for nectin-3 using immunohistochemistry in specimens of human OC and correlated these results with overall survival (OS). The nectin-3 expression was significantly increased accompanied by a degree of malignancy in ovarian tumors; moreover, the expression of matrix metallopeptidases (MMP) 2 and 9 was upregulated. In addition, an increased level of nectin-3 was related to a poorer OS. In summary, we have demonstrated that cellular migration and invasion via nectin-3 mediate the upregulation of MMP2 and MMP9 in OC cells. Nectin-3 may be a new biomarker for OC diagnosis.


Subject(s)
Biomarkers, Tumor/biosynthesis , Matrix Metalloproteinase 2/biosynthesis , Matrix Metalloproteinase 9/biosynthesis , Nectins/biosynthesis , Ovarian Neoplasms/metabolism , Up-Regulation/physiology , Adolescent , Adult , Aged , Female , Humans , Middle Aged , Ovarian Neoplasms/mortality , Ovarian Neoplasms/pathology , Survival Rate/trends , Young Adult
6.
Biosci Rep ; 38(5)2018 10 31.
Article in English | MEDLINE | ID: mdl-30054423

ABSTRACT

Endometrial carcinoma is the most common gynecological malignancy. The pathological factors triggering this disease are largely unknown. Although the role of guanine nucleotide-binding protein subunit α (GNA) 11 (GNA11) in melanoma has been described, the involvement of GNA14 in endometrial carcinoma remains to be determined. Here, we found that GNA14 expression was increased in endometrial carcinoma tissues compared with simple hyperplasia tissues. Based on lentivirus-mediated knockdown assay, we showed that GNA14 silencing significantly suppressed the proliferation of both HEC-1-A and Ishikawa cells. The caspase 3/caspase 7 activity and apoptosis were enhanced by GNA14 knockdown. GNA14 depletion led to cell cycle arrest at the G2/M phase. In addition, Apoptosis Array analysis revealed that caspase-3 and Fas were up-regulated by GNA14 knockdown. Our study suggests that GNA14 silencing blunts endometrial carcinoma cell proliferation. Targetting GNA14 may bring help for the patients of endometrial carcinoma.


Subject(s)
Endometrial Neoplasms/genetics , Endometrial Neoplasms/pathology , GTP-Binding Protein alpha Subunits, Gq-G11/genetics , Apoptosis/genetics , Caspase 3/genetics , Caspase 3/metabolism , Caspase 7/genetics , Caspase 7/metabolism , Cell Cycle Checkpoints/genetics , Cell Line, Tumor , Cell Proliferation/genetics , Female , GTP-Binding Protein alpha Subunits, Gq-G11/metabolism , Gene Expression Regulation, Neoplastic , Gene Knockdown Techniques , Gene Silencing , Humans , fas Receptor/genetics , fas Receptor/metabolism
7.
Int J Surg ; 34: 35-40, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27519498

ABSTRACT

OBJECTIVE: The study aimed to evaluate the clinical outcomes of laparoscopic nerve-sparing radical hysterectomy (LNRH) for bulky-stage cervical cancer (lesion ≥ 6 cm) after neoadjuvant chemotherapy (NAC). METHODS: This study prospective recruited patients with pathology-confirmed cervical cancer presenting as a bulky mass (lesion ≥ 6 cm). Subjects included patients who underwent laparoscopic radical surgery. They were assigned to one of two groups by surgical method: patients who underwent LNRH after NAC and patients who underwent classical laparoscopic radical hysterectomy (LRH) after NAC. We compared the patients' general clinical characteristics, surgical profiles, pathological findings and adjuvant therapies between the two groups. Recovery of bladder and intestinal function was evaluated by questionnaire. Patients were followed for up to 1 year to determine the maintenance of effect. RESULTS: Compared with patients treated with LRH, patients who underwent LNRH presented no significant differences in age, surgery characteristics, pathological findings, adjuvant therapies or main adverse effects. The mean duration of residual urine <50 mL in the LNRH group was 11 days, much shorter than that in the LRH group (18 days; P < 0.001). The period of passage of gas by anus was shorter (38.9 ± 4.1 h) in LNRH patients than that in LRH patients (56.5 ± 4.0 h; P < 0.001). The urinary and intestinal symptoms were evaluated 1 year after surgery. The recovery of urinary and intestinal function of patients was better in the LNRH group than in the LRH group. CONCLUSION: LNRH is a safe and feasible surgical management for bulky-stage cervical cancer patients (lesion ≥ 6 cm), and after NAC, the urinary and intestinal function of patients in LNRH group showed better recovery compared with functions in the LRH group. The technique is relatively new, and its oncologic efficiency has not yet been fully established. Prospective randomised controlled studies with an increased number of patients and long-term postoperative follow-up should be carried out to investigate the effect of this therapeutic strategy for bulky-stage cervical cancer.


Subject(s)
Hysterectomy/methods , Laparoscopy/methods , Uterine Cervical Neoplasms/therapy , Adult , Cohort Studies , Combined Modality Therapy , Female , Humans , Middle Aged , Neoadjuvant Therapy , Neoplasm Staging , Prospective Studies
8.
Indian J Cancer ; 53(1): 8-11, 2016.
Article in English | MEDLINE | ID: mdl-27146728

ABSTRACT

OBJECTIVES: Loss of Tumor Suppressor in Lung Cancer 1(TSLC1) was observed in many different cancers, but there were only limited research on TSLC1 gene and its roles in cancer suppression in ovarian cancer. This study explores the relationship between TSLC1 gene expression and the ovarian epithelial cancer. MATERIALS AND METHODS: Expression levels of TSLC1 were detected by immunohistochemical staining on formal-fixed paraffin embedded pathological specimen. A total of 259 samples were collected, including 24 benign ovarian tumor and 235 malignant ovarian cancers among them. RESULTS: Suppressed expression of TSLC1 protein was observed in 87.8% of poorly differentiated, 85.1% of moderately differentiated, and 46% of well differentiated ovarian epithelial cancers, respectively. There were none suppressed TSLC1 expression in benign ovarian tumor. Kruskal-Wallis test showed a significant association between the expression levels of TSLC1 gene and the degree of ovarian cancer differentiation (P < 0.001). CONCLUSIONS: Decreased expression of TSLC1 is associated with the differentiation in ovarian epithelial cancer. TSLC1 might be used as a molecular marker of severity in early stage ovarian cancer, and to help differentiating benign and malignant ovarian tumors.


Subject(s)
Cell Adhesion Molecules/genetics , Immunoglobulins/genetics , Neoplasms, Glandular and Epithelial/genetics , Ovarian Neoplasms/genetics , Biomarkers, Tumor/biosynthesis , Biomarkers, Tumor/genetics , Carcinoma, Ovarian Epithelial , Cell Adhesion Molecule-1 , Cell Adhesion Molecules/biosynthesis , Cell Differentiation/genetics , Female , Genes, Tumor Suppressor , Humans , Immunoglobulins/biosynthesis , Middle Aged , Neoplasms, Glandular and Epithelial/metabolism , Neoplasms, Glandular and Epithelial/pathology , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology
9.
Toxicol Mech Methods ; 24(2): 136-41, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24304007

ABSTRACT

Sodium fluoride (NaF) has been found to interfere with the reproductive system of animals. However, the cellular mechanisms underlying the reproductive toxicity of fluoride are unclear. The present study aims to define a possible mechanism of NaF-induced reproductive toxicity with respect to mineral, oxidative stress and c-Fos expression and the role of aluminum (Al) in intervening the toxic effect of NaF on rat testes. Fifty-six male Wistar rats were treated with normal saline, 1.0, 2.0, and 3.0 mg NaF/kg body weight (bw)/day, and each NaF concentration plus Al ion (0.1 mg Al(3+)/kg bw/day). After 90 days, no significant changes in the contents of Fe and Cu were observed in any of the NaF-treated groups compared with those of the control group. There were, however, significant decreases in the contents of Ca in the 1.0 mg NaF group, Zn in all NaF-treated groups and Mg in the 3.0 mg NaF group. The levels of malondialdehyde (MDA) in the 1.0 mg NaF group and hydrogen peroxide (H2O2) in the 2.0 mg NaF group significantly increased, whereas the activity of nitric oxide synthase (NOS) significantly decreased in the 1.0 mg NaF group. Meanwhile, the protein expression of c-Fos increased significantly in the 1.0 and 2.0 mg NaF groups compared with the control group. Conversely, these changes were partially attenuated in rats simultaneously administered Al. The present study suggested that NaF could decrease the contents of Ca, Fe and Mg and enhance oxidative stress leading to c-Fos overexpression, and some deleterious effects were more prominent at lower NaF intake. Furthermore, Al within the research concentration could minimize reproductive toxicity caused by fluoride.


Subject(s)
Aluminum/pharmacology , Oxidative Stress/drug effects , Proto-Oncogene Proteins c-fos/metabolism , Sodium Fluoride/toxicity , Testis/drug effects , Animals , Dose-Response Relationship, Drug , Male , Malondialdehyde/metabolism , Nitric Oxide/metabolism , Nitric Oxide Synthase/metabolism , Organ Size/drug effects , Rats , Rats, Wistar , Spectrophotometry, Atomic , Testis/enzymology , Testis/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...